These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 7667604)

  • 1. Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242.
    Pasanen P; Eskelinen M; Kulju A; Penttilä I; Janatuinen E; Alhava E
    Scand J Clin Lab Invest; 1995 Apr; 55(2):119-24. PubMed ID: 7667604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer.
    Eskelinen M; Pasanen P; Kulju A; Janatuinen E; Miettinen P; Poikolainen E; Tarvainen R; Nuutinen P; Pääkkönen M; Alhava E
    Anticancer Res; 1994; 14(3B):1427-32. PubMed ID: 8067718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
    Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
    Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Anticancer Res; 1995; 15(6B):2731-7. PubMed ID: 8669855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.
    Peters-Engl C; Medl M; Ogris E; Leodolter S
    Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small intestinal mucin antigen (SIMA); a novel tumour marker in colorectal cancer?
    Eskelinen M; Pasanen P; Janatuinen E; Pettersson N; Linnane A; Alhava E
    Anticancer Res; 1995; 15(5B):2351-6. PubMed ID: 8572651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the probability of cancer with several tumor markers in patients with colorectal disease.
    Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Järvinen H; Haglund C
    Oncology; 2004; 66(4):296-302. PubMed ID: 15218297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen.
    Huber K; Kirchheimer JC; Sedlmayer A; Bell C; Ermler D; Binder BR
    Cancer Res; 1993 Apr; 53(8):1788-93. PubMed ID: 8467497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
    Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
    Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CA 242 in comparison with established tumour markers in colorectal, pancreatic and lung cancer.
    Hasholzner U; Stieber P; Reiter W; Zimmermann A; Hofmann K; Schalhorn A
    Anticancer Res; 1999; 19(4A):2477-80. PubMed ID: 10470177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-associated trypsin inhibitor (TATI) in patients with colorectal carcinoma. A critical comparison with CEA.
    Catarino M; Conde R
    Scand J Clin Lab Invest Suppl; 1991; 207():43-6. PubMed ID: 1780689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
    Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
    Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
    Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
    Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CEA, CA 50 and CA 242 in patients surviving colorectal cancer without recurrent disease.
    Engarås B; Kewenter J; Nilsson O; Wedel H; Hafström L
    Eur J Surg Oncol; 2001 Feb; 27(1):43-8. PubMed ID: 11237491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour-associated trypsin inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and alpha1-antitrypsin in patients with gastrointestinal malignancies.
    Solakidi S; Dessypris A; Stathopoulos GP; Androulakis G; Sekeris CE
    Clin Biochem; 2004 Jan; 37(1):56-60. PubMed ID: 14675563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour-associated trypsin inhibitor TATI is a prognostic marker in colorectal cancer.
    Koskensalo S; Hagström J; Louhimo J; Stenman UH; Haglund C
    Oncology; 2012; 82(4):234-41. PubMed ID: 22508321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serological studies on CEA, CA 19-9, STn and SLX in colorectal cancer.
    Sato T; Nishimura G; Nonomura A; Miwa K; Miyazaki I
    Hepatogastroenterology; 1999; 46(26):914-9. PubMed ID: 10370638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening.
    Järvisalo J; Hakama M; Knekt P; Stenman UH; Leino A; Teppo L; Maatela J; Aromaa A
    Cancer; 1993 Mar; 71(6):1982-8. PubMed ID: 8443749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-associated trypsin inhibitor (TATI) in benign and malignant gastric disease.
    Loizate Toricaguena A; Lamiquiz Vallejo A; Dominguez Merru-Urrutia MJ; Legorburu Escudero JF
    Scand J Clin Lab Invest Suppl; 1991; 207():59-62. PubMed ID: 1780694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.